Abstract 3598
Background
Based on KEYNOTE-045 (NCT02256436), pembro was approved for the treatment of locally advanced or metastatic UC that progresses during or after a platinum-containing regimen. Updated results after >3 y of follow-up since the last patient (pt) was randomized are presented.
Methods
Pts with histologically or cytologically confirmed UC, progression after platinum-containing chemo, ECOG PS 0-2, measurable disease per RECIST v1.1, or ≤ 2 lines of systemic therapy were eligible. Pts were randomly assigned 1:1 to receive pembro 200 mg Q3W or investigator’s choice of paclitaxel 175 mg/m2 Q3W, docetaxel 75 mg/m2 Q3W, or vinflunine 320 mg/m2 Q3W. Primary end points: OS and PFS (RECIST v1.1, blinded central review). ORR and duration of response (DOR) were key secondary end points.
Results
As of Nov 30, 2018, among 542 enrolled pts (pembro, 270; chemo, 272), median (range) follow-up was 40.9 mo (36.6-48.9). Median OS was significantly longer with pembro vs chemo (10.1 vs 7.2 mo; HR, 0.72; P = 0.0003). OS rates at 24 mo were 26.9% with pembro and 14.2% with chemo. 36-mo OS rates were 20.7% and 11.0%, respectively. OS benefit with pembro vs chemo was maintained regardless of age, ECOG PS, prior therapy, liver metastases, baseline hemoglobin, time from last chemo, histology, risk factors, and chemo choice. Median PFS was similar between arms (2.1 vs 3.3 mo; HR, 0.96; P = 0.32). Median DOR for responders was longer with pembro than chemo (29.7 mo [1.6+ to 42.7+] vs 4.4 mo [1.4+ to 42.8+]), and a greater proportion of responses lasted ≥24 mo (56.8% vs 28.3%, Kaplan-Meier). Median survival follow-up for responders was 39.6 mo for pembro and 17.7 mo for chemo. ORR was higher with pembro vs chemo (21.1% vs 11.0%). Fewer patients given pembro vs chemo experienced a treatment-related adverse event of any grade (62.0% vs 90.6%) and a grade ≥3 adverse event (16.9% vs 50.2%).
Conclusions
With 3 y of follow-up, pembro continued to exhibit an OS benefit and superior safety vs chemo in pts with locally advanced or metastatic UC that progressed during or after platinum-based chemo. Pts who responded to pembro experienced a durable response with a median of > 2 y.
Clinical trial identification
NCT02256436, October 3, 2014.
Editorial acknowledgement
Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA), funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
A. Necchi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Rainier Therapeutics; Honoraria (self), Advisory / Consultancy, Spouse / Financial dependant: Bayer; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Clovis. Y. Fradet: Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Astellas; Research grant / Funding (institution), Travel / Accommodation / Expenses: TerSera; Research grant / Funding (institution): IMV Inc. J. Bellmunt: Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre-Fabre; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Honoraria (self), Honoraria (institution), Research grant / Funding (self), Research grant / Funding (institution): Takeda; Shareholder / Stockholder / Stock options: Biocline; Travel / Accommodation / Expenses: UpToDate. R. de Wit: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Research grant / Funding (institution): Bayer; Honoraria (self): Janssen; Advisory / Consultancy: Clovis. J. Lee: Honoraria (self): Novartis Korea; Honoraria (self): BMS Korea; Advisory / Consultancy: Pfizer Korea; Advisory / Consultancy: Janssen; Advisory / Consultancy: Sanofi Aventis; Advisory / Consultancy: Astellas Korea; Advisory / Consultancy: Ipsen Korea; Leadership role: Korea Cancer Study Group. L. Fong: Research grant / Funding (institution), Dr. Fong reports grants from Merck, during the conduct of the study; grants from Merck, outside the submitted work: Merck. N.J. Vozelgang: Full / Part-time employment: US Oncology; Advisory / Consultancy: Amgen, Pfizer, Bayer, Genentech/Roche, HERON, AstraZeneca, Caris Life Sciences, Fujifilm, Tolero Pharmaceuticals; Speaker Bureau / Expert testimony: Bayer, Sanofi, Genentech/Roche, Bristol-Myers Squibb, Exelixis, AstraZeneca/MedImmune; Travel / Accommodation / Expenses: Genentech/Roche, US Oncology, Pfizer, Bayer/Onyx, Exelixis, AstraZeneca/MedImmune; Shareholder / Stockholder / Stock options: Caris Life Sciences; Honoraria (self): UpToDate, Pfizer; Research grant / Funding (institution): US Oncology, Endocyte, Merck, Kintor. M.A. Climent: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre-Fabre. D.P. Petrylak: Advisory / Consultancy: Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, Urogen; Shareholder / Stockholder / Stock options: Bellicum, Tyme; Research grant / Funding (institution): Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics. T.K. Choueiri: Honoraria (self), Advisory / Consultancy: AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, NCCN, Michael J.; Advisory / Consultancy: AstraZeneca, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group.; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation Medicine Inc., Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Takeda; Speaker Bureau / Expert testimony, Leadership role: NCI GU Steering Committee (unpaid), Past Chairman of Medical and Scientific Steering Committee at the Kidney Cancer Association (unpaid). W.R. Gerritsen: Advisory / Consultancy: Bristol-Myers Squibb, Amgen, Merck Sharp & Dohme, Aglaia BioMedical Ventures, Astellas Pharma, Bayer, Janssen-Cilag; Research grant / Funding (institution): Astellas Pharma, Bayer, Janssen-Cilag; Travel / Accommodation / Expenses: Amgen, Bayer. H. Gurney: Advisory / Consultancy: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Ipsen; Advisory / Consultancy: MSD. D.I. Quinn: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy: Exelixis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech; Honoraria (self), Advisory / Consultancy: Roche; Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Astellas. S. Culine: Advisory / Consultancy: Bayer; Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Research grant / Funding (institution): Pfizer; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: MSD. C.N. Sternberg: Honoraria (self): Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy: Clovis; Advisory / Consultancy: BMS; Advisory / Consultancy: Incyte; Advisory / Consultancy: AstraZeneca; Research grant / Funding (institution): Janssen. K. Nam: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. T.L. Frenkl: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck & Co., Inc. J.L. Godwin: Full / Part-time employment: Merck & Co., Inc. D.F. Bajorin: Advisory / Consultancy, Research grant / Funding (institution), Membership on an advisory board or board of directors: Merck; Advisory / Consultancy, Membership on an advisory board or board of directors: Genentech; Advisory / Consultancy, Membership on an advisory board or board of directors: Bristol-Myers Squibb; Advisory / Consultancy, Membership on an advisory board or board of directors: Urogen; Advisory / Consultancy, Research grant / Funding (institution), Membership on an advisory board or board of directors: Novartis. D.J. Vaughn: Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Astellas.
Resources from the same session
3073 - 1 patient 3 different advance Ca nurse’s roles: symptom management&continuum care through a joint approach in a clinical case
Presenter: Catarina Almeida
Session: Poster Display session 3
Resources:
Abstract
4527 - Identification of malnutrition risk factors in patients with cancer in the first nursing visit
Presenter: Amaia Valverde
Session: Poster Display session 3
Resources:
Abstract
2904 - Engaging Cancer Survivors, Healthcare Providers and Advocates in The Development of a Colorectal Cancer Survivorship Information Resource: A Participatory Action Research Study
Presenter: Amanda Drury
Session: Poster Display session 3
Resources:
Abstract
3435 - Medical nurses’ experiences of the care-needs of adult patients with a primary brain tumour
Presenter: Jamila Mohammed
Session: Poster Display session 3
Resources:
Abstract
857 - Feasibility and acceptability of a mHealth intervention to increase colonoscopy uptake among Chinese first-degree relatives: a pilot cluster randomized controlled trial
Presenter: Yang Bai
Session: Poster Display session 3
Resources:
Abstract
1087 - Cancer patient participation and compliance in microbiome sample collection: an oncology research nurse’s experience
Presenter: Julie Malo
Session: Poster Display session 3
Resources:
Abstract
2783 - Implementing Digital Individual Care plans for Patients with Head and Neck cancer- Challenges and opportunities
Presenter: Helena Ullgren
Session: Poster Display session 3
Resources:
Abstract
1152 - The Effect of the Short-term and Long-term Compassion Fatigue Resiliency Program on the Quality of Life, Perceived Stress and Psychological Resilience of Oncology-Hematology Nurses
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
1172 - Competing risk analyses of overall survival and cancer-specific survival in patients with orbital rhabdomyosarcoma after surgery: a large cohort study
Presenter: Yu Zhang
Session: Poster Display session 3
Resources:
Abstract
5949 - Communication of genetic information to family members in hereditary cancers and healthcare providers’ role
Presenter: Carla Pedrazzani
Session: Poster Display session 3
Resources:
Abstract